Role of oral tetracyclines in preventing acneiform rash in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review [0.03%]
口服四环素类药物预防表皮生长因子受体酪氨酸激酶抑制剂所致非小细胞肺癌患者丘疹脓疱性皮疹的疗效：系统综述
Rita Morais Magalhães Marques de Sousa,Bárbara Raquel Lopes Vieira Granja,Sofia Beatriz Loureiro Marques de Vasconcelos Magina
Rita Morais Magalhães Marques de Sousa
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the current first-line therapy for non-small cell lung cancer (NSCLC). Acneiform rash is a common adverse effect of this treatmen...
Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated with a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry [0.03%]
西班牙Biobadaderm注册登记中的肿瘤坏死因子抑制剂治疗失败的患者中白细胞介素-17和白细胞介素-23抑制剂的生存率分析
Raquel Rivera-Díaz,Alicia Quesada,Antonio Sahuquillo-Torralba et al.
Raquel Rivera-Díaz et al.
Interleukin 12/23 inhibitors (IL-12/23i) and interleukin 17 and 23 inhibitors (IL-17i and IL-23i) represent the drug classes with the most favorable expectations for therapeutic response. However, the introduction of biosimilars has led man...
Accessibility as a key factor in the clinical evolution and therapeutic management of patients with hidradenitis suppurativa [0.03%]
痤疮样毛囊炎临床病程和治疗管理中的关键因素——可及性问题不容忽视
F J León Pérez,C García Moronta,S M Haselgruber de Francisco et al.
F J León Pérez et al.
Background and objective: Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory disease with a substantial impact on quality of life. Accessibility to specialised units and referral methods may significantl...
EVALUATION OF THE EFFICACY OF PHOTOPROTECTIVE FORMULATIONS APPLIED IN CONJUNCTION WITH TOPICAL ACTIVE INGREDIENTS IN PATIENTS WITH PHOTODERMATOSES [0.03%]
评估与外用活性成分联合使用的物理性防晒化妆品对光敏皮肤病患者的防晒效果
R Castillo-Muñoz,J Aguilera,E Navarrete-De Gálvez et al.
R Castillo-Muñoz et al.
Background: One of the main strategies in the prevention of photodermatoses is the use of topical sunscreens, which sometimes must be applied together with topical drugs specific for the dermatosis with the possibility th...
Cutaneous infections caused by Pseudomonas aeruginosa. Clinical presentation, diagnosis and treatment [0.03%]
铜绿假单胞菌的皮肤感染：临床表现、诊断和治疗
D Hartmann,J Ibaceta Ayala,D Morgado-Carrasco
D Hartmann
Pseudomonas aeruginosa is a gram-negative opportunistic bacillus of great relevance in dermatology due to its ability to cause a wide spectrum of skin infections. These infections can be characterized by a greenish discoloration and a disti...
Clascoterone 1% in the treatment of acne: a review of its efficacy, safety, and therapeutic positioning" [0.03%]
克列可酮治疗痤疮的疗效、安全性和定位分析——文献回顾
P Balado-Simó,M Brufau-Cochs,D Morgado-Carrasco
P Balado-Simó
Topical clascoterone (TC) is the first topical antiandrogen approved by the Food and Drug Administration (FDA) for the treatment of acne and is currently under evaluation for approval in Europe. Through bibliographic searches in Medline and...
SEVERE CUTANEOUS SIGNS OF HIPERSENSITIVITY TO DRUGS IN A PEDIATRIC HOSPITAL [0.03%]
一所儿童医院中严重与药物过敏反应相关的皮肤表现
H M Suárez-Bustamante,J A Alonso-Cadenas,L Noguera Morel et al.
H M Suárez-Bustamante et al.
Background: An adverse drug reaction (ADR) is a harmful and unintended response to drugs administered in therapeutic doses. Among these, cutaneous adverse reactions (CARs) are one of the most frequent clinical forms, whic...
Translation, cross-cultural adaptation, correlation with other PROMs and validation of the MF/SS-CTCL-QoL questionnaire on quality of life in mycosis fungoides (MF) and Sézary syndrome (SS) [0.03%]
MF/SS-CTCL-QoL问卷的翻译、跨文化改编、与其他PROMS的相关性及在皮肤T细胞淋巴瘤（MF和SZ）的生活质量量表上的验证研究
M M Onteniente-Gomis,S I Palencia Perez,F J Ortiz de Frutos et al.
M M Onteniente-Gomis et al.
Background: MF/SS-CTCL-QoL is the first specific questionnaire to measure the quality of life (QoL) of patients with Mycosis Fungoides (MF) and Sézary Syndrome (SS). It was developed by the Cutaneous Lymphoma Foundation....
Cost-consequence analysis of secukinumab vs adalimumab in moderate-to-severe hidradenitis suppurativa [0.03%]
关于中重度汗腺炎患者使用苏金单抗与阿达木单抗的费用结果分析
A Martorell Calatayud,A Molina-Leyva,A Jiménez Morales et al.
A Martorell Calatayud et al.
Background and objective: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Treatment for moderate-to-severe HS includes biologic therapies (adalimumab and secukinumab), resulting in increased disease ...